Skip to main content
Erschienen in: International Journal of Hematology 3/2016

27.05.2016 | Case Report

Late relapsing mantle cell lymphoma showing preserved sensitivity to single-agent lenalidomide

verfasst von: Adrian Tempescul, Jean-Christophe Ianotto, Cristina Bagacean, Pierre-Yves Salaun, Corina Bocsan, Mihnea Zdrenghea

Erschienen in: International Journal of Hematology | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Mantle cell lymphoma is a hematologic malignancy characterized by poor therapeutic outcomes. Immunomodulatory drugs are a focus of attention in this disease, especially for the elderly and frail patients not able to tolerate the typically intensive therapeutic approaches used in fitter patients. We here present the case of refractory mantle cell lymphoma of the elderly that achieved complete remission following the use of single-agent lenalidomide, and a second complete response to the same regimen on relapse 5 years later.
Literatur
1.
Zurück zum Zitat Swerdlow SH. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: WHO Press; 2008. Swerdlow SH. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: WHO Press; 2008.
2.
3.
Zurück zum Zitat Tempescul A, Ianotto JC, Morel F, Marion V, De Braekeleer M, Berthou C. Lenalidomide, as a single agent, induces complete remission in a refractory mantle cell lymphoma. Ann Hematol. 2009;88(9):921–2.CrossRefPubMed Tempescul A, Ianotto JC, Morel F, Marion V, De Braekeleer M, Berthou C. Lenalidomide, as a single agent, induces complete remission in a refractory mantle cell lymphoma. Ann Hematol. 2009;88(9):921–2.CrossRefPubMed
4.
Zurück zum Zitat Vose JM. Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management. Am J Hematol. 2015;90(8):739–45.CrossRefPubMed Vose JM. Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management. Am J Hematol. 2015;90(8):739–45.CrossRefPubMed
5.
Zurück zum Zitat Witzens-Harig M, Hess G, Atta J, Zaiss M, Lenz G, Scholz C, et al. Current treatment of mantle cell lymphoma: results of a national survey and consensus meeting. Ann Hematol. 2012;91(11):1765–72.CrossRefPubMed Witzens-Harig M, Hess G, Atta J, Zaiss M, Lenz G, Scholz C, et al. Current treatment of mantle cell lymphoma: results of a national survey and consensus meeting. Ann Hematol. 2012;91(11):1765–72.CrossRefPubMed
6.
Zurück zum Zitat Mussetti A, Kumar A, Dahi PB, Perales MA, Sauter CS. Lifting the mantle: unveiling new treatment approaches in relapsed or refractory mantle cell lymphoma. Blood Rev. 2015;29(3):143–52.CrossRefPubMed Mussetti A, Kumar A, Dahi PB, Perales MA, Sauter CS. Lifting the mantle: unveiling new treatment approaches in relapsed or refractory mantle cell lymphoma. Blood Rev. 2015;29(3):143–52.CrossRefPubMed
7.
Zurück zum Zitat Avivi I, Goy A. Refining the mantle cell lymphoma paradigm: impact of novel therapies on current practice. Clin Cancer Res. 2015;21(17):3853–61.CrossRefPubMed Avivi I, Goy A. Refining the mantle cell lymphoma paradigm: impact of novel therapies on current practice. Clin Cancer Res. 2015;21(17):3853–61.CrossRefPubMed
9.
Zurück zum Zitat Kritharis A, Coyle M, Sharma J, Evens AM. Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities. Blood. 2015;125(16):2471–6.CrossRefPubMedPubMedCentral Kritharis A, Coyle M, Sharma J, Evens AM. Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities. Blood. 2015;125(16):2471–6.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Habermann TM, Lossos IS, Justice G, Vose JM, Wiernik PH, McBride K, et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol. 2009;145(3):344–9.CrossRefPubMed Habermann TM, Lossos IS, Justice G, Vose JM, Wiernik PH, McBride K, et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol. 2009;145(3):344–9.CrossRefPubMed
11.
Zurück zum Zitat Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma. Ann Oncol. 2011;22(7):1622–7.CrossRefPubMed Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma. Ann Oncol. 2011;22(7):1622–7.CrossRefPubMed
12.
Zurück zum Zitat Goy A, Sinha R, Williams ME, Kalayoglu Besisik S, Drach J, Ramchandren R, et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol. 2013;31(29):3688–95.CrossRefPubMedPubMedCentral Goy A, Sinha R, Williams ME, Kalayoglu Besisik S, Drach J, Ramchandren R, et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol. 2013;31(29):3688–95.CrossRefPubMedPubMedCentral
Metadaten
Titel
Late relapsing mantle cell lymphoma showing preserved sensitivity to single-agent lenalidomide
verfasst von
Adrian Tempescul
Jean-Christophe Ianotto
Cristina Bagacean
Pierre-Yves Salaun
Corina Bocsan
Mihnea Zdrenghea
Publikationsdatum
27.05.2016
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 3/2016
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-016-2020-4

Weitere Artikel der Ausgabe 3/2016

International Journal of Hematology 3/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.